MannKind Stock Makes Moves on Milestone Payment

Short sellers have targeted MNKD stock

Deputy Editor
Apr 1, 2019 at 9:58 AM
facebook twitter linkedin


Biopharmaceutical concern MannKind Corporation (NASDAQ:MNKD) is volatile today, after the company received a $12.5 million milestone payment from United Therapeutics (UTHR). The payment is part of a collaboration agreement -- worth up to $37.5 million in milestone payments for MNKD -- to develop and commercialize MNKD's hypertension treatment as a dry powder formula. After jumping 1.5% out of the gate,  the shares were last seen down 2.5% at $1.92.

The equity rallied hard off its December low of $0.94, and hit a six-month high of $2.34 on March 20. The shares have since pulled back below the $2 mark -- a 23.6% Fibonacci retracement of that recent surge, and a layer of resistance last June and October. The penny stock is still up 81.5% year-to-date, though. 

While analysts are relatively quiet on MannKind, the two brokerages that do follow the drugmaker give it "buy" and "strong buy" ratings. Plus the consensus 12-month target price of $3.50 represents an 82.3% premium to current levels, and sits in an area not seen since January 2018. 

Short sellers, meanwhile, have piled on their bearish bets. Short interest rose 5.4% in the latest reporting period, and now accounts for a solid 21.6% of the stock's available float, or 10 times the security's average daily trading volume.

 

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners